IL313006A - טיפול במחלות והפרעות הקשורות ל-fgg - Google Patents
טיפול במחלות והפרעות הקשורות ל-fggInfo
- Publication number
- IL313006A IL313006A IL313006A IL31300624A IL313006A IL 313006 A IL313006 A IL 313006A IL 313006 A IL313006 A IL 313006A IL 31300624 A IL31300624 A IL 31300624A IL 313006 A IL313006 A IL 313006A
- Authority
- IL
- Israel
- Prior art keywords
- fgg
- diseases
- treatment
- disorders associated
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286393P | 2021-12-06 | 2021-12-06 | |
| PCT/US2022/080933 WO2023107896A1 (en) | 2021-12-06 | 2022-12-05 | Treatment of fgg related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313006A true IL313006A (he) | 2024-07-01 |
Family
ID=86731325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313006A IL313006A (he) | 2021-12-06 | 2022-12-05 | טיפול במחלות והפרעות הקשורות ל-fgg |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250043281A1 (he) |
| EP (1) | EP4444884A4 (he) |
| JP (1) | JP2024542632A (he) |
| KR (1) | KR20240132537A (he) |
| CN (1) | CN118647722A (he) |
| AU (1) | AU2022405510A1 (he) |
| CA (1) | CA3238996A1 (he) |
| IL (1) | IL313006A (he) |
| MX (1) | MX2024006828A (he) |
| WO (1) | WO2023107896A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024254091A1 (en) * | 2023-06-05 | 2024-12-12 | Empirico Inc. | Treatment of fgg related diseases and disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130040844A1 (en) * | 2010-01-28 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
| WO2013130868A1 (en) * | 2012-02-29 | 2013-09-06 | Isis Pharmaceuticals, Inc. | Methods for modulating fibrinogen expression |
| AU2013243949A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| JP6758184B2 (ja) * | 2013-08-27 | 2020-09-23 | シーアールシー・フォー・メンタル・ヘルス・リミテッドＣｒｃ Ｆｏｒ Ｍｅｎｔａｌ Ｈｅａｌｔｈ Ｌｔｄ | 神経疾患のバイオマーカーを同定するための方法および神経疾患の診断 |
-
2022
- 2022-12-05 WO PCT/US2022/080933 patent/WO2023107896A1/en not_active Ceased
- 2022-12-05 CA CA3238996A patent/CA3238996A1/en active Pending
- 2022-12-05 EP EP22905270.9A patent/EP4444884A4/en active Pending
- 2022-12-05 CN CN202280091048.0A patent/CN118647722A/zh active Pending
- 2022-12-05 IL IL313006A patent/IL313006A/he unknown
- 2022-12-05 MX MX2024006828A patent/MX2024006828A/es unknown
- 2022-12-05 KR KR1020247022505A patent/KR20240132537A/ko active Pending
- 2022-12-05 JP JP2024532156A patent/JP2024542632A/ja active Pending
- 2022-12-05 AU AU2022405510A patent/AU2022405510A1/en active Pending
- 2022-12-05 US US18/714,537 patent/US20250043281A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3238996A1 (en) | 2023-06-15 |
| WO2023107896A9 (en) | 2024-07-11 |
| WO2023107896A1 (en) | 2023-06-15 |
| EP4444884A1 (en) | 2024-10-16 |
| EP4444884A4 (en) | 2025-04-16 |
| AU2022405510A1 (en) | 2024-07-04 |
| JP2024542632A (ja) | 2024-11-15 |
| US20250043281A1 (en) | 2025-02-06 |
| CN118647722A (zh) | 2024-09-13 |
| KR20240132537A (ko) | 2024-09-03 |
| MX2024006828A (es) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280710A (he) | שיטות והרכבים לטיפול במחלות מיטוכונדריות או הפרעות והטרופלסמיות | |
| IL288214A (he) | נגזרות של קוינאזולין-4-און שימושיות לטיפול במחלות והפרעות הקשורות ל-braf | |
| ZA202212876B (en) | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders | |
| IL287032A (he) | תכשירים ושיטות לשיפור בריאות העור ולטיפול ומניעה של מחלות, הפרעות ומצבים הקשורים במיקרואורגניזמים מחוללי מחלות | |
| EP3920923A4 (en) | Therapeutic agents and methods of treatment | |
| IL262608A (he) | טיפול משולב בהפרעות ובמחלות דלקתיות בעיניים | |
| EP3634442A4 (en) | METHODS OF TREATMENT AND PREVENTION OF DISEASES | |
| IL286268A (he) | פרידופידין לטיפול במחלות והפרעות מיטוכונדריאליות וסימפטומים הקשורות למחלות אלו | |
| IL269083A (he) | שיטות למניעה ולטיפול במחלות לב | |
| AU2021381324A9 (en) | Methods of treating diseases and disorders | |
| EP4054713A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING SKIN DISEASES AND DISORDERS USING LEKTI | |
| EP4251753A4 (en) | TREATMENT OF DISEASES AND DISORDERS RELATED TO SOS2 | |
| IL313006A (he) | טיפול במחלות והפרעות הקשורות ל-fgg | |
| IL309317A (he) | טיפול במחלות והפרעות הקשורות ל- mtres1 | |
| EP4355430A4 (en) | TREATMENT OF DISEASES AND DISORDERS RELATED TO MST1R | |
| IL304673A (he) | חומצות פחמימות מונו-ודי-פחמימות פונקציונליות עם שרשרת ארוכה ונגזרות שלהן, והשימוש בהן למניעה או טיפול במחלות | |
| IL309315A (he) | טיפול במחלות והפרעות הקשורות ל- mst1 | |
| IL321373A (he) | טיפול במחלות והפרעות הקשורות ל- mst1 | |
| EP4034563A4 (en) | Tnfrsf25-mediated treatments of immune diseases and disorders | |
| EP4355355A4 (en) | TREATMENT OF PLIN1-ASSOCIATED DISEASES AND DISORDERS | |
| GB2574747B (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | |
| IL307205A (he) | טיפול סביב-נגעי במצבי עור | |
| EP4252760A4 (en) | THERAPEUTIC AGENT FOR NERVOUS DISORDERS | |
| HK40116588A (en) | Treatment of fgg related diseases and disorders | |
| IL321120A (he) | טיפול במחלות והפרעות הקשורות ל-mtres1 |